Physician profile
Michael L Macmurray
NPI 1386660280
$700.35
in general payments reported to CMS, 2019-2025
18 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2021: $32.15 · 2022: $18.23 · 2023: $14.44 · 2024: $96.71 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $166.24 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.28 | 2019 | |
| Hologic Sales and Service, LLC | $67.99 | 2024-2025 | Aptima |
| Abbvie INC. | $39.36 | 2025 | |
| Amarin Pharma, INC. | $33.43 | 2019-2021 | |
| Pfizer INC. | $32.79 | 2021-2022 | |
| Novo Nordisk INC | $30.50 | 2025 | Wegovy |
| Allergan, INC. | $29.99 | 2019 | |
| Merck Sharp & Dohme LLC | $28.51 | 2019-2025 | Enflonsia, Rotateq, Capvaxive |
| Dexcom, INC. | $21.33 | 2024 | Dexcom G6 Transmitter |
| Valeritas, INC. | $21.00 | 2019 | |
| Amgen INC. | $19.94 | 2019 | |
| Astellas Pharma US INC | $16.69 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $13.53 | 2024 | |
| Mannkind Corporation | $13.26 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.15 | 2019 | |
| Sanofi Pasteur INC. | $13.01 | 2019 | |
| Lilly USA, LLC | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Macmurray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.